Treatment of brain metastases of small cell lung cancer with teniposide.

Abstract:

:Over 50% of patients with small cell lung cancer (SCLC) will develop symptomatic brain metastases during the course of their disease. Results of whole brain radiotherapy, the standard treatment, are rather poor and relapses are frequent. Thus, new modes of therapy are urgently needed for these patients. In this study, the efficacy of teniposide was evaluated at a dose of 150 mg/m2 intravenously on days 1, 3, and 5 at 3-week intervals. In 11 of 26 evaluable patients an intracranial response was observed. Median response duration was 23 weeks (range, 9 to 50). Toxicity was acceptable, with grades 3/4 leukocytopenia and thrombocytopenia reported in 37% and 16%, respectively, of 123 courses. Therefore, teniposide is an effective agent against brain metastases of SCLC and is suitable for palliation of these patients.

journal_name

Semin Oncol

journal_title

Seminars in oncology

authors

Postmus PE,Smit EF,Berendsen HH,Sleijfer DT,Haaxma-Reiche H

subject

Has Abstract

pub_date

1992-04-01 00:00:00

pages

89-94

issue

2 Suppl 6

eissn

0093-7754

issn

1532-8708

pii

0093-7754(92)90319-V

journal_volume

19

pub_type

杂志文章
  • Additional chemotherapy agents improve treatment outcome for children and adults with advanced B-cell lymphomas.

    abstract::We report the updated results of an intensive treatment protocol for children (< 18 years) and adults (> or = 18 years) with advanced B-cell lymphomas. The protocol consists of two chemotherapy regimens: A, consisting of cyclophosphamide, doxorubicin, vincristine and high-dose methotrexate (CODOX-M), and B, consisting...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:

    authors: Adde M,Shad A,Venzon D,Arndt C,Gootenberg J,Neely J,Nieder M,Owen W,Seibel N,Wilson W,Horak ID,Magrath I

    更新日期:1998-04-01 00:00:00

  • Prolonging remission with rituximab maintenance therapy.

    abstract::Maintenance therapy using rituximab is currently under consideration as a means of prolonging remission in patients with indolent non-Hodgkin's lymphoma. A phase II trial using rituximab as first-line therapy followed by maintenance treatment was carried out in patients with previously untreated indolent non-Hodgkin's...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Hainsworth JD

    更新日期:2004-02-01 00:00:00

  • Antineoplastic activity of continuous exposure to dexrazoxane: potential new role as a novel topoisomerase II inhibitor.

    abstract::Although originally developed as an antitumor agent in the 1970s, dexrazoxane (DEX) is currently used as a cardioprotective agent in combination with doxorubicin (DOX). Due to concerns about anthracycline-induced cardiotoxicity at higher cumulative doses, many investigators have chosen to administer DOX by prolonged i...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Synold TW,Tetef ML,Doroshow JH

    更新日期:1998-08-01 00:00:00

  • The role of zoledronic acid in cancer: clinical studies in the treatment and prevention of bone metastases.

    abstract::Preclinical studies with zoledronic acid (Zometa; Novartis Pharmaceuticals Corp, East Hanover, NJ) have shown its potential in malignant bone disease. Clinical studies in the treatment of hypercalcemia of malignancy have been completed, as have phase I and II trials in patients with cancer and pre-existing bone metast...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,随机对照试验,评审

    doi:10.1016/s0093-7754(01)90260-x

    authors: Coleman RE,Seaman JJ

    更新日期:2001-04-01 00:00:00

  • Intraperitoneal chemotherapy in the management of ovarian cancer.

    abstract::Initial phase I trials of intraperitoneal chemotherapy in ovarian cancer patients demonstrated that a pharmacologic advantage was achieved with the direct instillation of drugs into the peritoneal cavity. Recent trials have reported that approximately 30% of patients who have small-volume residual disease following in...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Ozols R

    更新日期:1985-09-01 00:00:00

  • Mechanisms of drug resistance in breast cancer.

    abstract::Drug resistance is one of the most important problems in the treatment of cancer. Patients become resistant not only to the drugs used initially, but also those to which they have not yet been exposed. A number of factors influence the therapeutic outcome of patients with breast cancer, foremost of which is the tumor ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Dalton WS

    更新日期:1990-08-01 00:00:00

  • Fatigue: definitions, mechanisms, and paradigms for study.

    abstract::Interferon-alpha (IFN-alpha) therapy is frequently associated with significant fatigue, which is often the dominant dose-limiting side effect. The fatigue associated with IFN-alpha therapy is usually dose related, worsens with continued therapy, and is associated with significant depression. Although the direct cause ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Dalakas MC,Mock V,Hawkins MJ

    更新日期:1998-02-01 00:00:00

  • The history of ifosfamide.

    abstract::Ifosfamide was developed by investigators at Asta-Werke in Germany. Its chemical structure differs from that of cyclophosphamide by the transposition of one of the side chain chloroethyl groups to the ring nitrogen. In several preclinical models, ifosfamide had greater activity than cyclophosphamide. It produced less ...

    journal_title:Seminars in oncology

    pub_type: 历史文章,杂志文章

    doi:

    authors: Loehrer PJ Sr

    更新日期:1992-12-01 00:00:00

  • Sarcoma in the young adult population: an international view.

    abstract::The outcomes in young adults aged 20-39 with sarcoma tend to be inferior compared to those in children and adolescents. There are differences in sarcoma histotype distribution with age, such that pediatric-type tumors predominate in the 20- to 25-year-old group while more adult-type sarcomas occur in those aged 35-39 ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2009.03.006

    authors: Soliman H,Ferrari A,Thomas D

    更新日期:2009-06-01 00:00:00

  • High-dose megestrol acetate in the treatment of advanced breast cancer.

    abstract::A dose-response relationship has long been suspected for progestin compounds in the treatment of breast cancer, but only recently have trials been implemented to investigate this issue. In 1985, we began a phase I-II study of high-dose megestrol acetate in dosages of 480 mg/d to 1,600 mg/d in heavily pretreated postme...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Tchekmedyian NS,Tait N,Abrams J,Aisner J

    更新日期:1988-04-01 00:00:00

  • Radiation Therapy Oncology Group (RTOG) studies in head and neck cancer.

    abstract::Since its foundation in 1971, the RTOG has conducted a successful clinical research program in head and neck mucosal squamous cell carcinoma with 22 treatment protocols and one registry study which combined have accumulated data on over 5,500 patients. The RTOG was the first multicenter group to evaluate neoadjuvant c...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Marcial VA,Pajak TF,Kramer S,Davis LW,Stetz J,Laramore GE,Jacobs JR,Al-Sarraf M,Brady LW

    更新日期:1988-02-01 00:00:00

  • Practical considerations and radiation safety in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).

    abstract::90Y ibritumomab tiuxetan (Zevalin; Biogen Idec Inc, Cambridge, MA), the first radioimmunotherapeutic agent approved by the US Food and Drug Administration, is a promising treatment option in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma, including patients wit...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2003.10.003

    authors: Gordon LI

    更新日期:2003-12-01 00:00:00

  • CPT-11: clinical experience in phase I studies.

    abstract::Phase I studies of CPT-11 (irinotecan) have been conducted in Europe, the United States, and Japan to determine the maximum tolerated dose (MTD) and the most appropriate intravenous administration schedule for further evaluation in phase II investigations. Diarrhea and/or neutropenia were the major dose-limiting toxic...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Armand JP

    更新日期:1996-02-01 00:00:00

  • Recently identified peptides involved in the regulation of body weight.

    abstract::The application of molecular and genetic techniques to the study of body weight regulation have produced exciting new insights into the physiological systems governing energy expenditure, appetite, and metabolic signaling. A number of new peptides have been identified that play important roles in these regulatory syst...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Bessesen DH,Faggioni R

    更新日期:1998-04-01 00:00:00

  • Evaluation of new drugs in small cell lung cancer: the activity of gemcitabine.

    abstract::The evaluation of the activity of new drugs against small cell lung cancer (SCLC) is discussed and the results with gemcitabine are presented. Gemcitabine has activity against untreated SCLC. Preliminary results from an ongoing study also indicate activity in so-called resistant SCLC. ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Postmus PE,Schramel FM,Smit EF

    更新日期:1998-08-01 00:00:00

  • Prostate cancer vaccines: current status.

    abstract::Recent insights into cell-mediated immunotherapy have led to a wave of new trials involving immunotherapy for prostate cancer. Vaccines have evolved from nonspecific immune stimulants like Bacillus Calmette-Guerin (BCG) to much more specific and potent strategies. Techniques currently being investigated include passiv...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Hwang LC,Fein S,Levitsky H,Nelson WG

    更新日期:1999-04-01 00:00:00

  • Neoadjuvant Treatment for Pancreatic Cancer.

    abstract::Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with limited effective therapeutic options and exceedingly high mortality rates. Currently, cure can only be achieved through resection, however the vast majority of patients present with advanced disease for which upfront surgery is not an option. In...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2018.12.002

    authors: Raufi AG,Manji GA,Chabot JA,Bates SE

    更新日期:2019-02-01 00:00:00

  • Topotecan and the treatment of recurrent ovarian cancer: is there a role for granulocyte colony-stimulating factor?

    abstract::Topotecan (Hycamtin; SmithKline Beecham Pharmaceuticals, Philadelphia, PA) a new chemotherapeutic agent for the treatment of patients with advanced carcinoma of the ovary after failure of initial or subsequent therapy, is a specific, potent inhibitor of the enzyme topoisomerase I. Myelosuppression is the dose-limiting...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Saltz L,Janik JE

    更新日期:1997-02-01 00:00:00

  • Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: an update of a US intergroup trial (SW0G S9003).

    abstract::We report an update on a prospective observational trial for Waldenstrom's macroglobulinemia (WM) that called for re-registration to treatment with fludarabine (30 mg/m(2)) upon the development of symptomatic or progressive disease. Patients who did not require therapy for more than 1 year (n = 54) could be distinguis...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:10.1053/sonc.2003.50050

    authors: Dhodapkar MV,Jacobson JL,Gertz MA,Crowley JJ,Barlogie B

    更新日期:2003-04-01 00:00:00

  • Front-line therapy for advanced colorectal cancer: emphasis on chemotherapy.

    abstract::For four decades, 5-fluorouracil was the only option available for patients with metastatic colorectal cancer. It provided a response rate of 15% to 20%, with a median survival of approximately 1 year. In the past 5 years, remarkable progress has been made in colorectal cancer research with the approval of irinotecan ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2005.04.022

    authors: Varadhachary GR,Hoff PM

    更新日期:2005-12-01 00:00:00

  • African American men, prostate cancer early detection examination use, and informed decision-making.

    abstract::It is well known that African American men are more likely to be diagnosed with metastatic prostate cancer than White men. Racial variation in the use of prostate cancer early detection modalities (ie, digital rectal examination [DRE] and prostate-specific antigen [PSA] testing) has been suggested as a major reason fo...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Myers RE

    更新日期:1999-08-01 00:00:00

  • Genetic changes associated with testicular cancer susceptibility.

    abstract::Testicular germ cell tumor (TGCT) is a highly heritable cancer primarily affecting young white men. Genome-wide association studies (GWAS) have been particularly effective in identifying multiple common variants with strong contribution to TGCT risk. These loci identified through association studies have implicated mu...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2016.08.004

    authors: Pyle LC,Nathanson KL

    更新日期:2016-10-01 00:00:00

  • Improving patient care through molecular diagnostics.

    abstract::Traditional cancer diagnostic techniques include assessment of histologic appearance, identification of specific tumor subtypes, tumor grading, assessment of lymph node status, and presence of metastasis. These are useful for initial evaluation, but are limited in their ability to predict response to treatment and/or ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2004.07.017

    authors: Perez EA,Pusztai L,Van de Vijver M

    更新日期:2004-10-01 00:00:00

  • Current antiretroviral therapy and its impact on human immunodeficiency virus-related wasting.

    abstract::Recent improvements in the management of people living with human immunodeficiency virus (HIV) disease in the United States have led to remarkable reductions in HIV-related morbidity and mortality. The Centers for Disease Control and Prevention recently reported substantial reductions in acquired immunodeficiency synd...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Sherer R

    更新日期:1998-04-01 00:00:00

  • Metastatic breast cancer: preliminary results with oral hormonal therapy.

    abstract::Hormonal therapy is very effective in the treatment of patients with metastatic breast cancer. Response to various therapies leads to improved quality of life and prolonged survival. This clinical trial compared two commonly utilized additive hormonal agents, tamoxifen citrate and megestrol acetate (Megace). Prelimina...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Allegra JC,Bertino J,Bonomi P,Byrne P,Carpenter J,Catalano R,Creech R,Dana B,Durivage H,Einhorn L

    更新日期:1985-12-01 00:00:00

  • Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy in stage II and III breast cancer patients: preliminary results of a phase II and pharmacogenomic study.

    abstract::The purpose of this study is to evaluate the efficacy and safety of a biweekly neoadjuvant docetaxel/gemcitabine regimen in patients with histologically confirmed stage II and III breast cancer. In addition, a cDNA microarray study attempted to correlate pretreatment gene-expression profile with clinical and pathologi...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:10.1053/j.seminoncol.2004.03.025

    authors: Estévez LG,Sánchez-Rovira P,Dómine M,León A,Calvo I,Jaén A,Casado V,Rubio G,Daz M,Miró C,Lobo F

    更新日期:2004-04-01 00:00:00

  • Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.

    abstract::Advanced-stage mantle cell lymphoma (MCL) is a disease for which no curative treatment strategy exists. Results with standard combination chemotherapy, with or without an anthracycline, are disappointing, and new and better therapies are needed. High-dose therapy and autologous stem-cell transplantation (ASCT) have be...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,评审

    doi:

    authors: Mangel J,Buckstein R,Imrie K,Spaner D,Crump M,Tompkins K,Reis M,Perez-Ordonez B,Deodhare S,Romans R,Pennell N,Robinson JB,Hewitt K,Richardson P,Lima A,Pavlin P,Berinstein NL

    更新日期:2002-02-01 00:00:00

  • Involvement of platelet-derived microparticles in tumor progression and thrombosis.

    abstract::Platelet-derived microparticles (PMPs) represent the most abundant microparticle (MP) subtype. Their presence reflects platelet activity, physiopathology, and the thrombotic state of cancer patients. The quantity and composition of PMPs strictly depends on the way MPs were generated. Because platelets play a key role ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2014.04.010

    authors: Mezouar S,Mege D,Darbousset R,Farge D,Debourdeau P,Dignat-George F,Panicot-Dubois L,Dubois C

    更新日期:2014-06-01 00:00:00

  • From monoclonal antibodies to chimeric antigen receptors for the treatment of human malignancies.

    abstract::Monoclonal antibodies (mAbs) and their directly derived cell-based application known as chimeric antigen receptors (CARs) ensue from the need to develop novel therapeutic strategies that retain high anti-tumor activity, but carry reduced toxicity compared to conventional chemo- and radiotherapies. In this concise revi...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2014.08.005

    authors: Caruana I,Diaconu I,Dotti G

    更新日期:2014-10-01 00:00:00

  • MicroRNAs in mutagenesis, genomic instability, and DNA repair.

    abstract::MicroRNAs (miRNAs) are aiding our understanding of cancer biology, and are now coming close to therapeutic use as well. Here, we focus specifically on the interaction between miRNAs and genomic instability. MiRNA regulation is essential to many cellular processes, and escape from this regulatory network seems to be a ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2011.08.003

    authors: Landau DA,Slack FJ

    更新日期:2011-12-01 00:00:00